Reflux revisited: advancing the role of pepsin

Karna Dev Bardhan, Vicki Strugala, Peter W Dettmar, Karna Dev Bardhan, Vicki Strugala, Peter W Dettmar

Abstract

Gastroesophageal reflux disease is mediated principally by acid. Today, we recognise reflux reaches beyond the esophagus, where pepsin, not acid, causes damage. Extraesophageal reflux occurs both as liquid and probably aerosol, the latter with a further reach. Pepsin is stable up to pH 7 and regains activity after reacidification. The enzyme adheres to laryngeal cells, depletes its defences, and causes further damage internally after its endocytosis. Extraesophageal reflux can today be detected by recognising pharyngeal acidification using a miniaturised pH probe and by the identification of pepsin in saliva and in exhaled breath condensate by a rapid, sensitive, and specific immunoassay. Proton pump inhibitors do not help the majority with extraesophageal reflux but specifically formulated alginates, which sieve pepsin, give benefit. These new insights may lead to the development of novel drugs that dramatically reduce pepsinogen secretion, block the effects of adherent pepsin, and give corresponding clinical benefit."For now we see through a glass, darkly."-First epistle, Chapter 13, Corinthians.

Figures

Figure 1
Figure 1
Example of pepsin profile from human gastric juice purified by HPAEC.

References

    1. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(4):1–78.
    1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. American Journal of Gastroenterology. 2006;101(8):1900–1920.
    1. Johnson N, Toohill, RJ. Effects, Diagnosis and Management of Extra-Esophageal Reflux. New York, NY, USA: Nova Science Publishers; 2010.
    1. Dettmar PW, Castell DO, Heading RC. Reflux and its consequences. Alimentary Pharmacology & Therapeutics. 2011;33(supplement 1):1–71.
    1. Savarino V, di Mario F, Scarpignato C. Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacological Research. 2009;59(3):135–153.
    1. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Current Opinion in Pharmacology. 2008;8(6):677–684.
    1. Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology. 1981;81(2):376–394.
    1. Winkelstein A. Peptic esophagitis. The Journal of the American Medical Association. 1935;104:906–909.
    1. Wolf EL. The esophagus. Mount Sinai Journal of Medicine. 2000;67(1):25–31.
    1. Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske FF. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969;56(2):223–230.
    1. Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Digestive Diseases and Sciences. 1981;26(1):65–72.
    1. Schweitzer EJ, Harmon JW, Bass BL, Batzri S. Bile acid efflux precedes mucosal barrier disruption in the rabbit esophagus. The American Journal of Physiology. 1984;247(5):G480–G485.
    1. Johnson LF, Harmon JW. Experimental esophagitis in a rabbit model. Clinical relevance. Journal of clinical gastroenterology. 1986;8:26–44.
    1. Gotley DC, Morgan AP, Cooper MJ. Bile acid concentrations in the refluxate of patients with reflux oesophagitis. British Journal of Surgery. 1988;75(6):587–590.
    1. Iffikhar SY, Ledingham S, Steele RJ, et al. Bile reflux in columnar-lined Barrett's oesophagus. Annals of the Royal College of Surgeons of England. 1993;75(6):411–416.
    1. Johnsson F, Joelsson B, Floren CH, Nilsson A. Bile salts in the esophagus of patients with esophagitis. Scandinavian Journal of Gastroenterology. 1988;23(6):712–716.
    1. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111(5):1192–1199.
    1. Kauer WK, Peters JH, DeMeester TR, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery. 1997;122(5):874–881.
    1. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598–602.
    1. Zhu H, Hart CA, Sales D, Roberts NB. Bacterial killing in gastric juice—effect of pH and pepsin on Escherichia coli and Helicobacter pylori. Journal of Medical Microbiology. 2006;55(9):1265–1270.
    1. Roberts NB. Human pepsin multiplicity and function: role in reflux disease. Alimentary Pharmacology and Therapeutics. 2006;24(2):2–9.
    1. Walker V, Taylor WH. Pepsin 5 in gastric juice: determination and relationship to the alkali-stable peptic activity. Gut. 1979;20(11):977–982.
    1. Pearson JP, Ward R, Allen A. Mucus degradation by pepsin: comparison of mucolytic activity of human pepsin 1 and pepsin 3: implications in peptic ulceration. Gut. 1986;27(3):243–248.
    1. Allen A, Hutton DA, Leonard AJ, Pearson JP, Sellars LA. Pepsins. In: John LW, editor. Endogenous Mediators of Gastrointestinal Disease. New York, NY, USA: CRC Press; 1990. pp. 53–69.
    1. Roberts NB, Taylor WH. Comparative pepstatin inhibition studies on individual human pepsins and pepsinogens 1,3 and 5(gastricsin) and pig pepsin A. Journal of Enzyme Inhibition and Medicinal Chemistry. 2003;18(3):209–217.
    1. Etherington DJ, Taylor WH. The pepsins of normal human gastric juice. Biochemical Journal. 1969;113(4):663–668.
    1. Tasker AL. Otitis media with effusion: key factors. University of Newcastle Upon Tyne; 2003. Ph.D. thesis.
    1. Campos LA, Sancho J. The active site of pepsin is formed in the intermediate conformation dominant at mildly acidic pH. FEBS Letters. 2003;538(1–3):89–95.
    1. Piper DW, Fenton BH. pH stability and activity curves of pepsin with special reference to their clinical importance. Gut. 1965;6(5):506–508.
    1. Johnston N, Dettmar PW, Bishwokarma B, Lively MO, Koufman JA. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope. 2007;117(6):1036–1039.
    1. Ten Kate RW, Tuynman HA, Festen HP, Pals G, Meuwissen SG. Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man. European Journal of Clinical Pharmacology. 1988;35(2):173–176.
    1. Babaei A, Bhargava V, Aalam S, Scadeng M, Mittal R. Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging. Alimentary Pharmacology and Therapeutics. 2009;29(8):863–870.
    1. Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Alimentary Pharmacology and Therapeutics. 2006;23(2):23–34.
    1. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 1996;110(3):725–732.
    1. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. Journal of Gastrointestinal Surgery. 2004;8(7):888–896.
    1. Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope. 2004;114(12):2129–2134.
    1. Johnston N, Wells CW, Blumin JH, Toohill RJ, Merati AL. Receptor-mediated uptake of pepsin by laryngeal epithelial cells. Annals of Otology, Rhinology and Laryngology. 2007;116(12):934–938.
    1. Franco RA, Jr., Deschler DG, Eamranond P. Laryngopharyngeal reflux. UpToDate ( ), vol. Version 17.3, 2009.
    1. Johnston N, Wells CW, Samuels TL, Blumin JH. Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. Annals of Otology, Rhinology and Laryngology. 2009;118(9):677–685.
    1. Johnston N, Dettmar PW, Lively MO, et al. Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease. Annals of Otology, Rhinology and Laryngology. 2006;115(1):47–58.
    1. Gill GA, Johnston N, Buda A, et al. Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin. Annals of Otology, Rhinology and Laryngology. 2005;114(12 I):913–921.
    1. Samuels TL, Handler E, Syring ML, et al. Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux. Annals of Otology, Rhinology and Laryngology. 2008;117(9):688–695.
    1. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128(3):771–778.
    1. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. American Journal of Gastroenterology. 2004;99(1):13–22.
    1. Farré R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut. 2010;59(2):164–169.
    1. Axford SE, Sharp N, Dettmar P, et al. Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies. Annals of Otology, Rhinology and Laryngology. 2001;110(12):1099–1108.
    1. Johnson LF, Demeester TR. Twenty four hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. American Journal of Gastroenterology. 1974;62(4):325–332.
    1. Oelschlager BK, Quiroga E, Isch JA, Cuenca-Abente F. Gastroesophageal and pharyngeal reflux detection using impedance and 24-hour pH monitoring in asymptomatic subjects: defining the normal environment. Journal of Gastrointestinal Surgery. 2006;10(1):54–62.
    1. Wiener GJ, Tsukashima R, Kelly C, et al. Oropharyngeal pH monitoring for the detection of liquid and aerosolized supraesophageal gastric reflux. Journal of Voice. 2009;23(4):498–504.
    1. Ayazi S, Lipham JC, Hagen JA, et al. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. Journal of Gastrointestinal Surgery. 2009;13(8):1422–1429.
    1. Strugala V, Dettmar PW, Morice AH. Detection of pepsin in sputum and exhaled breath condensate: could it be a useful marker for reflux-related respiratory disease? Gastroenterology. 2009;136:p. S1895.
    1. Vaezi MF. Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux. Nature Clinical Practice Gastroenterology and Hepatology. 2005;2(12):595–603.
    1. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. American Journal of Gastroenterology. 2004;99(6):1037–1043.
    1. Xiao YL, Lin JK, Cheung TK, et al. Normal values of 24-hour combined esophageal multichannel intraluminal impedance and pH monitoring in the Chinese population. Digestion. 2009;79(2):109–114.
    1. Zentilin P, Iiritano E, Dulbecco P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Digestive and Liver Disease. 2006;38(4):226–232.
    1. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Alimentary Pharmacology and Therapeutics. 2005;22(10):1011–1021.
    1. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 2010;32(3):334–343.
    1. Strugala V, McGlashan JA, Watson MG, et al. Evaluation of a non-invasive pepsin dipstick test for the diagnosis of extra-oesophageal reflux—results of a pilot study. Gastroenterology. 2007;132:A99–A100.
    1. Bredenoord AJ, Tutuian R, Smout AJ, Castell DO. Technology review: esophageal impedance monitoring. American Journal of Gastroenterology. 2007;102(1):187–194.
    1. D'Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. Journal of Thoracic and Cardiovascular Surgery. 2005;129(5):1144–1152.
    1. Ward C, Forrest IA, Brownlee IA, et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax. 2005;60(10):872–874.
    1. Tasker A, Dettmar PW, Panetti M, Koufman JA, Birchall JP, Pearson JP. Reflux of gastric juice and glue ear in children. Lancet. 2002;359(9305):p. 493.
    1. Klokkenburg JJ, Hoeve HL, Francke J, Wieringa MH, Borgstein J, Feenstra L. Bile acids identified in middle ear effusions of children with otitis media with effusion. Laryngoscope. 2009;119(2):396–400.
    1. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 2007;25(4):385–392.
    1. Reichel O, Dressel H, Wiederänders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngology: Head and Neck Surgery. 2008;139(3):414–420.
    1. Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut. 2007;56(12):1654–1664.
    1. Mastronarde JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. New England Journal of Medicine. 2009;360(15):1487–1499.
    1. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. British Medical Journal. 2006;332(7532):11–17.
    1. Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. American Journal of Gastroenterology. 1999;94(11):3131–3138.
    1. Baron JH, Gribble RJ, Holdstock DJ, Misiewicz JJ. Double-blind controlled trial of amylopectin sulphate (Depepsen) in the symptomatic treatment of duodenal ulcer. Gut. 1977;18(9):723–724.
    1. Cocking JB. A trial of amylopectin sulfate (SN-263) and propantheline bromide in the long term treatment of chronic duodenal ulcer. Gastroenterology. 1972;62(1):6–10.
    1. Landecker KD, McCallum EM, Fevre DI, et al. Effect of sodium amylosulfate (Depepsen) on the healing of duodenal ulcer. Gastroenterology. 1976;71(5):723–725.
    1. Bonnevie O, Svendsen LB, Holst-Christensen J, et al. Double-blind randomised clinical trial of a pepsin-inhibitory pentapeptide (pepstatin) in the treatment of duodenal ulcer. Gut. 1979;20(7):624–628.
    1. Strugala V, Avis J, Jolliffe IG, Johnstone LM, Dettmar PW. The role of an alginate suspension on pepsin and bile acids—key aggressors in the gastric refluxate. Does this have implications for the treatment of GORD? Journal of Pharmacy and Pharmacology. 2009;61(8):1021–1028.
    1. McGlashan JA, Johnstone LM, Strugala V, Dettmar PW. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. European Archives of Oto-Rhino-Laryngology. 2009;266(2):243–251.
    1. Strugala V, Dettmar PW. Alginate in the treatment of extra-oesophageal reflux. In: Johnson N, Toohill RJ, editors. Effects, Diagnosis and Management of Extra-Esophageal Reflux. New York, NY, USA: Nova Science Publishers; 2010. pp. 145–168.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere